Glucotrack, Inc. (Integrity Applications, Inc.) — Q1 2018 Form 10-Q
Reporting period: Three months ended March 31, 2018; filed May 15, 2018. The filing identifies the registrant as Integrity Applications, Inc., which develops and commercializes the GlucoTrack device. The company operates primarily through its Israeli subsidiary.
Business context and financial highlights
Integrity Applications is developing a non-invasive glucose monitor for people with Type 2 diabetes and prediabetes. The GlucoTrack DF-F had European CE Mark approval but was not approved for commercial sale in the United States. Commercial activity remained limited, with no material recurring operating revenue.
| Metric | Q1 2018 | Q1 2017 / comparison |
|---|---|---|
| Revenue | $28,209 | $96,237; down about 71% |
| Operating expenses | $1,938,018 | $2,695,837 |
| Operating loss | $1,909,809 | $2,599,600 |
| Net loss | $1,847,794 | $2,530,325 |
| Loss per share, basic and diluted | $0.34 | $0.48 |
| Cash used in operating activities | $1,426,868 | $1,146,113 |
| Cash and cash equivalents, March 31 | $314,387 | $53,782 at December 31, 2017 |
| Total current assets / current liabilities | $1,483,911 / $3,591,666 | Working capital deficit: about $2.11 million |
Gross profit and gross margin are not separately provided. Financing income was $62,015, largely reflecting fair-value changes in warrants. The company reported total liabilities of $4.77 million, including $179,423 in long-term stockholder loans and $815,899 in warrant liabilities. No material off-balance-sheet arrangements were reported.
Material changes and financing
- Revenue fell from the prior-year period, which included an initial Hong Kong customer order. Management attributed the lower Q1 2018 revenue to limited device and personal ear-clip sales.
- Net loss narrowed mainly because Q1 2017 included one-time management transition costs: severance, a signing bonus, recruiting fees, and related professional expenses. Selling and marketing expense rose to $308,637 from $236,939, reflecting the hiring of a Chief Commercialization Officer; R&D expense was broadly stable.
- The company raised approximately $1.7 million net in Q1 through a private placement of 435,556 Series D units, each including common stock and three five-year warrants. Financing cash inflow was $1.70 million, compared with $2.60 million in Q1 2017.
- After quarter-end, on May 10, 2018, the company raised $517,000 gross from another Series D unit closing. Common shares outstanding were 7,469,604 at March 31 and 7,584,492 as of May 15.
- Q1 operating cash use exceeded Q1 2017 despite the lower net loss. Cash at quarter-end was only $314,387.
Outlook, risks, and unusual items
- Going concern and liquidity: Management said available cash was expected to fund operations for less than one month from the filing date and that additional capital was required. The filing states that substantial doubt exists about the company’s ability to continue as a going concern; the financial statements contain no adjustments for the outcome. Future financing is uncertain.
- Operating plans: Management expected R&D, selling and marketing, and G&A expenses to increase during the remainder of 2018 and beyond, conditional on obtaining funding; spending may be adjusted to available resources.
- Commercialization: The company was preparing a Netherlands launch for Q2 2018 and targeting an Israel launch in Q3, with broader European rollout dependent on the pilot programs’ success. It had terminated or was reassessing some underperforming distributor relationships.
- Regulatory and product development: U.S. clinical trials were contingent on financing; management said it did not expect to commence them without at least $10 million of additional capital. The company also described planned work on wireless connectivity, digital-health applications, accuracy, miniaturization, and easier calibration.
- China exposure: On May 14, 2018, the company notified its China distributor of its intention to terminate the agreement unless breaches were cured within 30 days. Termination could significantly delay Chinese registration; without a replacement partner, distribution and CFDA approval would not be possible.
- Equity dilution and accounting: Q1 included stock-based compensation of $561,482 and stock dividends for Series B and C preferred holders. The company issued employee options for 767,500 shares at $4.50, and Series D and placement-agent warrants include anti-dilution features. Management was evaluating the impact of a new accounting standard for down-round features.
- Other obligations: Preferred dividends, including $4,700 cash dividends and approximately $503,892 in stock dividends, had not been paid as of the filing, with interest accruing at 9% annually on unpaid dividends. Future product sales are subject to Israeli government royalties; the disclosed contingent amount was about $34,717 excluding interest.
- The filing reports favorable prior clinical-study results, but also identifies risks including product acceptance, competition, regulatory requirements, manufacturing, and the company’s dependence on external financing. These statements are not assurance of future commercial or clinical success.
Important facts for investors to verify
- Cash runway and current financing needs, including how the May 10 placement proceeds affect the less-than-one-month runway statement.
- Whether the company can raise sufficient capital to fund operations, U.S. trials, and planned product development, and the resulting dilution and warrant overhang.
- Progress, sales, and reimbursement outcomes from the Netherlands and Israel pilot launches, and the status of distributor relationships.
- Resolution of the China distributor dispute and its effect on the timing and feasibility of CFDA registration.
- Regulatory and clinical milestones, including U.S. trial funding and the evidence supporting product accuracy and market readiness.
- The filing’s registrant is Integrity Applications, Inc., while the request metadata names Glucotrack, Inc.; confirm the intended issuer and applicable corporate identity.